These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1590209)

  • 21. Perspectives. Medicare doc pay change, big Part B premium hike on the way.
    Med Health; 2004 Mar; 58(13):1, 7-8. PubMed ID: 15088495
    [No Abstract]   [Full Text] [Related]  

  • 22. Part D resources for pharmacists.
    Armor BL
    J Pharm Pract; 2010 Apr; 23(2):144-5. PubMed ID: 21507808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abolition of Pharmaceutical Reimbursement Advisory Committee: final regulation.
    Fed Regist; 1978 Aug; 43(154):35310-1. PubMed ID: 10297140
    [No Abstract]   [Full Text] [Related]  

  • 24. Current issues in pharmaceutical reimbursement.
    Fijalka S; Fye D; Johnson PE
    Am J Health Syst Pharm; 2008 Jan; 65(2 Suppl 1):S11-26. PubMed ID: 18192243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Billing for outpatient transplant pharmacy services.
    Maldonado AQ; Seiger TC; Urann CL; McCleary JA; Goroski AL; Ojogho ON
    Am J Health Syst Pharm; 2012 Jan; 69(2):144-7. PubMed ID: 22215360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capitation for pharmacy services: rationale, findings, and future plans.
    Lipson DP; Yesalis CE; Norwood GJ
    Med Mark Media; 1980 Oct; 15(10):25-32. PubMed ID: 10249119
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluating the effects of Quebec's private-public drug insurance system.
    Morgan SG; Gagnon MA; Charbonneau M; Vadeboncoeur A
    CMAJ; 2017 Oct; 189(40):E1259-E1263. PubMed ID: 29018085
    [No Abstract]   [Full Text] [Related]  

  • 28. Revamping how pharmacists are paid.
    Martin S
    Am Pharm; 1993 Feb; NS33(2):62-5. PubMed ID: 8456748
    [No Abstract]   [Full Text] [Related]  

  • 29. Medicaid reimbursement.
    Berry MD
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-31. PubMed ID: 18345577
    [No Abstract]   [Full Text] [Related]  

  • 30. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals.
    Carlson JJ; Garrison LP; Sullivan SD
    J Manag Care Pharm; 2009 Oct; 15(8):683-7. PubMed ID: 19803557
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacists' acceptable levels of compensation for MTM services: a conjoint analysis.
    Wang J; Hong SH; Meng S; Brown LM
    Res Social Adm Pharm; 2011 Dec; 7(4):383-95. PubMed ID: 21272533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacists, Medicare Part D, and the antikickback statute.
    Greene A
    Am J Health Syst Pharm; 2006 Aug; 63(15):1435-7. PubMed ID: 16849708
    [No Abstract]   [Full Text] [Related]  

  • 33. Can health care costs be contained? Yes, says one third party fiscal intermediary.
    Kaplan SX
    Empl Benefits J; 1978; 3(4):10-3, 15. PubMed ID: 10294880
    [No Abstract]   [Full Text] [Related]  

  • 34. The MAC program and advisors to the government.
    Shubin S
    Hosp Formul; 1981 Aug; 16(8):869-72, 877-9. PubMed ID: 10252371
    [No Abstract]   [Full Text] [Related]  

  • 35. Reimbursement by capitation: it's new, controversial, and strengthens incentive.
    Norwood GJ; Yesalis C; Lipson D; Johnson N
    Am Pharm; 1979 Jan; 19(1):37-40. PubMed ID: 364969
    [No Abstract]   [Full Text] [Related]  

  • 36. Competitive incentive program. Analysis and proposal.
    Stone J
    Am Pharm; 1986 Jul; NS26(7):45-9. PubMed ID: 3529904
    [No Abstract]   [Full Text] [Related]  

  • 37. The piggyback dilemma.
    Tanner DJ
    Hosp Pharm; 1978 Jun; 13(6):326. PubMed ID: 10307644
    [No Abstract]   [Full Text] [Related]  

  • 38. Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists.
    Kirschenbaum BE
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S13-20. PubMed ID: 19966075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initiatives to control drug costs associated with an independent physician association.
    Abourjaily P; Kross J; Gouveia WA
    Am J Health Syst Pharm; 2003 Feb; 60(3):269-72. PubMed ID: 12613237
    [No Abstract]   [Full Text] [Related]  

  • 40. Quebec turnaround.
    Gariepy Y
    Am Pharm; 1993 Jul; NS33(7):5. PubMed ID: 8342498
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.